

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[About Us](#)
[Sloan Kettering Institute](#)

[Research](#)

[Education & Training](#)

[News & Events](#)

MOLECULAR PHARMACOLOGY PROGRAM

The David Scheinberg Lab

[Open Positions](#)

Molecular Pharmacology Program

Research



David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (*Blood*, 2010), and a vaccine to WT1 in Phase III trials. Read full article in [Science](#).

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular

proteins (*Science Trans. Med.*, 2013), (*Nature Biotech.*, 2015), as well as prototype targeted nano-machines (*Nature Nano*, 2013), and cellular micropharmacies (*Nature Chem.Biol.*, 2021).

Research Projects

[Projects](#)



Featured News



[At Work: Center for Experimental Therapeutics Chair David Scheinberg](#)

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

ANNOUNCEMENT



[Innovative Partnership Will Speed Drug Discovery and Development](#)

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

[Scientists ID Antibody That Might Boost Cancer Therapy](#)

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

[View All Featured News](#)

Publications Highlights

[Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5\(176\):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.](#)

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.


[View All Publications](#)


People




David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery
Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
MD, PhD, Johns Hopkins University School of Medicine

 scheinbd@mskcc.org
Email Address

 [646-888-2190](tel:646-888-2190)
Office Phone

 [View physician profile](#)
Physician profile



Members

Curcio
Research Assistant

Dao
Senior Research Scientist

Korotitsvii
Research Assistant

McDevitt
Laboratory Member




Samarah Forbes
Senior Administrative
Assistant


Zita Aretz
Graduate Student

Winson
Cai
Graduate Student

Annelisa Cornel
Research Fellow



Josh Jaeyop
Lee
Hematology/Oncology
Fellow



Qianqian (Skylar)
Lin
Graduate Student




Manish Malviya
Senior Research Scientist



Jeremy P.
Meyerberg
Research Technician




Stephanie
Pierre
Graduate Student



Sarah Qureshy
Medical Student Research
Fellow Education



Ekaterina Revskaya
Senior Research Scientist



Kristen
Vogt
Graduate Student



Patrick Wallisch
Graduate Student

Lab Alumni
+

Lab Affiliations
+

Lab News & Events

[Journal Club & Photo Album](#)

Get in Touch

✉ scheinbd@mskcc.org

Lab Head Email

☎ [646-888-2190](tel:646-888-2190)

Office Phone

☎ [646-888-2205](tel:646-888-2205)

Lab Phone

Lab Resources

+

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

Actinium

Equity; Intellectual Property Rights; Professional Services and Activities

Arvinas, Inc.

Equity

Atengen, Inc.

Equity; Professional Services and Activities (Uncompensated)

Bridge Medicines

Professional Services and Activities (Uncompensated)

Colmmune, Inc.

Equity; Intellectual Property Rights; Professional Services and Activities

Eureka Therapeutics Inc

Equity; Professional Services and Activities

Great Point Partners

Equity; Professional Services and Activities

Iovance Biotherapeutics, Inc.

Equity

Lantheus Medical Imaging, Inc.

Equity

OncoPep, Inc.

Professional Services and Activities

Pfizer, Inc.

Equity; Professional Services and Activities

Repertoire Immune Medicines, Inc.

Professional Services and Activities

Sapience Therapeutics, Inc.

Equity; Fiduciary Role / Position

Sellas Life Science Group

Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

▼ About Us

[Overview](#)

[Leadership](#)

[Administration](#)

[History](#)

[Contact Us](#)



▼ Research

[Overview](#)

[Research programs](#)

[Research labs](#)

[Core facilities & resources](#)

▾ Education & Training

[Overview](#)

[Postdoctoral training](#)

[Gerstner Sloan Kettering Graduate School](#)

[Joint graduate programs](#)

[Programs for college & high school students](#)

▾ News & Events

[Overview](#)

[Seminars & events](#)

▾ Open Positions

[Overview](#)

[Faculty positions](#)

[Postdoctoral positions](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center